RP1 in Primary Melanoma to Reduce the Risk of Sentinel Lymph Node Metastasis

Rate of Sentinel Lymph Node (SLN) Positivity

This early-phase study will examine Vusolimogene Oderparepvec, a genetically modified
 oncolytic viral strain of the herpes simplex type 1 (HSV-1) virus, with potential oncolytic,
 immunostimulating and antineoplastic activities. Upon administration, vusolimogene
 oderparepvec specifically targets, infects and replicates in tumor cells and does not infect
 healthy cells. This results in tumor cell lysis and the release of virus particles which
 infect and replicate within nearby tumor cells, resulting in tumor cel death. The immune
 system is activated by the released tumor-associated antigens (TAAs) from the tumor cells
 creating an anti-tumor immune response against the tumor cells, thereby further killing the
 tumor cells. The virus itself also elicits a tumor-specific systemic immune and cytotoxic
 T-lymphocyte (CTL) response, thereby killing nearby non-infected tumor cells.